No Data
No Data
Ruili Medical & Aesthetic (02135.HK) issued and allotted approximately 139 million new shares under the share offering
On April 25, Ge Longhui (02135.HK) issued an announcement. On April 25, 2024, approximately 139 million new shares will be issued and allocated in accordance with the share offering.
Ruili Medical Aesthetic (02135): The share offering was oversubscribed by about 31.7% and raised about HK$19.2 million
According to Zhitong Finance App News, Ruili Medical & Aesthetic (02135) announced that since all conditions contained in the underwriting agreement have been met, and the underwriter did not terminate the underwriting agreement before the final termination time limit, the stock offering was becoming unconditional at 4:00 p.m. on April 18, 2024 (Thursday). The net proceeds from the stock offering were approximately HK$19.2 million. In total, it has received 8 provisional quota notices and valid applications under additional application forms, involving a total of approximately 183 million shares offered, which is equivalent to about 131.7% of the total number of shares offered for subscription under the offering. Based on the above results, shares were sold
瑞麗醫美(新):2023年報
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
Ruili Medical & Aesthetic (02135) announced annual results, loss attributable to shareholders of 32.457 million yuan, an increase of 103.99% year-on-year
According to the Zhitong Finance App, Ruili Medical & Aesthetic (02135) announced annual results for the year ended December 31, 2023. The group achieved revenue of 189 million yuan (RMB, same below) during the period, an increase of 15.11% over the previous year; losses attributable to shareholders were 32.457 million yuan, an increase of 103.99% over the previous year; and the basic loss per share was 7.77 points. According to the announcement, the main reason for the increase in revenue and continued losses is that in the first month of 2023, the business of medical institutions in Zhejiang and Anhui regions was still affected by the large-scale COVID-19 outbreak, which prevented most customers from visiting the group's institutions, making the company
瑞麗醫美:截至2023年12月31日止年度年度業績公告
No Data